B. Shen

Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Jin Y. Jin, Yuan Chen, S. Girish, 2014, Clinical Pharmacokinetics.

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

M. Sliwkowski, R. Scheller, L. Khawli, 2012, Nature Biotechnology.

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

L. Friberg, J. Tibbitts, B. Bender, 2014, The AAPS Journal.

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice

L. Khawli, Minhong Yan, S. Ross, 2014, mAbs.

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

D. Heimbrook, B. Higgins, K. Kolinsky, 2009, Molecular Cancer Therapeutics.

Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.

S. Girish, B. Shen, Keyang Xu, 2015, Bioanalysis.

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.

A. Kamath, B. Fine, F. Brunstein, 2016, Regulatory toxicology and pharmacology : RTP.

Pharmacokinetics and ADME characterizations of antibody-drug conjugates.

J. Tibbitts, B. Shen, Kedan Lin, 2013, Methods in molecular biology.